Professor Zhou Aiping's team and Professor Shen Lin's team join hands to add new evidence for target-immune combination therapy for biliary tract cancer research

On May 1, 2022, Pr.

The study performed a pooled analysis of two Phase Ib clinical trials (TQB2450-Ib-05 and TQB2450-Ib-08 trials) conducted at two centers during the same period, including a total of 66 patients with advanced BTC who had progressed after first-line chemotherapy ( Including 2 patients who were not suitable or refused to receive first-line chemotherapy), treated with anlotinib combined with TQB2450 (a novel PD-L1 inhibitor), which showed good efficacy and tolerabili.

The median follow-up time was 168 months, and the median PFS and OS were 24 (95% CI: 11-25) and 177 (95% CI: 174-171) months, respectively (Figure

FigureKaplan-Meier curves of (A) PFS and (B) OS for all patients

Most BTC patients have so far lacked effective second-line treatmen.

Therefore, new second-line treatment strategies are urgently needed for advanced biliary tract tumo.

The study also carried out in-depth biomarker analysis to identify potential predictors of efficacy and provide guidance and reference for precise treatment and screening of dominant populatio.

Figure(A) Kaplan-Meier curve of PFS in patients with TMB≥5 and TMB<5; (B) Kaplan-Meier curve of OS in patients with TMB≥5 and TMB<5

Figure(A) Kaplan-Meier curve of PFS in patients with KRAS mutation and KRAS wild type; (B) Kaplan-Meier curve of OS in patients with KRAS mutation and KRAS wild type

Professor Zhou Jun from Peking University Cancer Hospital and Professor Sun Yongkun from Cancer Hospital, Chinese Academy of Medical Sciences are the co-first authors of the artic.